Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

84.27USD
22 Oct 2018
Change (% chg)

$-3.70 (-4.21%)
Prev Close
$87.97
Open
$88.50
Day's High
$88.50
Day's Low
$83.50
Volume
1,629,902
Avg. Vol
1,538,107
52-wk High
$125.84
52-wk Low
$83.50

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

Financials

  ABBV.N Industry Sector
P/E (TTM): 22.10 30.90 33.64
EPS (TTM): 4.09 -- --
ROI: 11.74 14.75 14.27
ROE: 113.57 16.24 15.99

AbbVie CFO Chase to retire by mid-year 2019

AbbVie Inc said on Friday that William Chase stepped down as chief financial officer and will retire from the company in mid-2019, and the U.S. drugmaker promoted controller, Robert Michael, to the CFO role.

19 Oct 2018

UPDATE 2-AbbVie CFO Chase to retire by mid-year 2019

Oct 19 AbbVie Inc said on Friday that William Chase stepped down as chief financial officer and will retire from the company in mid-2019, and the U.S. drugmaker promoted controller, Robert Michael, to the CFO role.

19 Oct 2018

AbbVie names Robert Michael chief financial officer

Oct 19 AbbVie Inc on Friday appointed Robert Michael as its chief financial officer, replacing William Chase, who will retire in mid-2019.

19 Oct 2018

AbbVie settles Humira biosimilar dispute with Fresenius Kabi

U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug.

18 Oct 2018

AbbVie settles Humira biosimilar dispute with Fresenius Kabi

Oct 18 U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug.

18 Oct 2018

Samsung launches third rival to AbbVie's Humira drug in EU

LONDON South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales.

17 Oct 2018

Samsung launches third rival to AbbVie's Humira drug in EU

LONDON, Oct 17 South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales.

17 Oct 2018

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

LONDON Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States.

16 Oct 2018

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

LONDON, Oct 16 Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States.

16 Oct 2018

BRIEF-Sandoz Launches Biosimilar Version Of Abbvie's Humira In UK

* NOVARTIS UNIT SANDOZ LAUNCHES HYRIMOZ, ITS BIOSIMILAR VERSION OF ABBVIE'S HUMIRA, IN UK AS OF OCT 16; OTHER EUROPEAN MARKETS TO FOLLOW -SPOKESMAN Further company coverage: (Reporting by UK bureau)

16 Oct 2018

Earnings vs. Estimates